These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Sharp's syndrome: a new entity amongst the connective tissue diseases?]. Kahn MF; Peltier AP; Appelboom T Nouv Presse Med; 1975 Jun; 4(25):1863-5. PubMed ID: 1080278 [TBL] [Abstract][Full Text] [Related]
6. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases. Sharp GC; Irvin WS; May CM; Holman HR; McDuffie FC; Hess EV; Schmid FR N Engl J Med; 1976 Nov; 295(21):1149-54. PubMed ID: 1086429 [TBL] [Abstract][Full Text] [Related]
10. [The clinical significance of soluble nuclear antigen specific antibodies (author's transl)]. Peltier AP; Gaudreau A; Amor B; Kahn MF; Ryckewaert A; Sany J; Haim T Nouv Presse Med; 1978 May; 7(21):1813-8. PubMed ID: 307737 [TBL] [Abstract][Full Text] [Related]
11. Patterns of clinical disease associated with antibodies to nuclear ribonucleoprotein. Maddison PJ; Mogavero H; Reichlin M J Rheumatol; 1978; 5(4):407-11. PubMed ID: 310884 [TBL] [Abstract][Full Text] [Related]
12. Speckled (particulate) epidermal nuclear IgG deposition in normal skin. Correlation of clinical features and laboratory findings in 46 patients with a subset of connective tissue disease characterized by antibody to extractable nuclear antigen. Prystowsky SD; Tuffanelli DL Arch Dermatol; 1978 May; 114(5):705-10. PubMed ID: 348115 [TBL] [Abstract][Full Text] [Related]
14. Clinical implications of ribonucleoprotein antibody. Rasmussen EK; Ullman S; Høier-Madsen M; Sørensen SF; Halberg P Arch Dermatol; 1987 May; 123(5):601-5. PubMed ID: 3495241 [TBL] [Abstract][Full Text] [Related]
15. Case control study of antibodies to ENA in progressive systemic sclerosis patients. Furst DE; Obrodovic M; Barnett EV; Clements PJ; Paulus HE J Rheumatol; 1984 Jun; 11(3):298-305. PubMed ID: 6610753 [TBL] [Abstract][Full Text] [Related]
16. Antibodies against extractable nuclear antigens (ENA) in systemic scleroderma. Jabłońska S; Błaszczyk M; Górkiewicz A; Jarzabek-Chorzelska M; Rzesa G; Chorzelski T Arch Immunol Ther Exp (Warsz); 1978; 26(1-6):765-8. PubMed ID: 312085 [TBL] [Abstract][Full Text] [Related]
17. Antibodies to components of extractable nuclear antigen. Clinical characteristics of patients. Farber SJ; Bole GG Arch Intern Med; 1976 Apr; 136(4):425-31. PubMed ID: 1083722 [TBL] [Abstract][Full Text] [Related]
18. [Significance of speckled staining of epidermal nuclei in direct immunofluorescence. 10 cases (author's transl)]. Morel P; Peltier AP; Allegre P; Civatte J Nouv Presse Med; 1978 Jul 1-8; 7(27):2377-80. PubMed ID: 353722 [TBL] [Abstract][Full Text] [Related]
19. In vivo antinuclear antibodies (ANA) in biopsies of normal skin: diagnostic significance and relation to serum ANA. Kallenberg CG; de Jong MC; Walstra TM; Kardaun S; The TH J Rheumatol; 1983 Oct; 10(5):733-40. PubMed ID: 6606041 [TBL] [Abstract][Full Text] [Related]
20. Clinical and laboratory characteristics of patients with speckled pattern antinuclear antibodies. McMillan SA; Fay AC; Taggart AJ; McCrea JD; Roberts SD; Boyd MW; Nelson JK; Haire M Ulster Med J; 1986 Oct; 55(2):112-7. PubMed ID: 3492803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]